• TK 210 ELISA
    New unique method for early detection of progressive disease

  • We measure what really matters!

Welcome to AroCell

We develop and commercialize new and unique tests for the prognosis, monitoring of treatment and relapse, and follow-up of cancer.

TK 210 ELISA

Early detection of progressive tumor disease may be important for clinical management. Our unique new product TK 210 ELISA is the only available standard test to measure TK1 protein concentration in serum and offers a step towards individualized cancer therapy. We measure what really matters!

Read more

Research & References

AroCell presented its TK 210 ELISA blood test as a robust tool for researchers and clinicians at the congress of the International Society of Oncology and Biomarkers in Zakopane, Poland. The test results presented show good sensitivity and performance in measuring TK1 protein in serum.

Read more

Latest news

Meet us at the events listed in our calendar and keep updated on AroCell by our press releases, reports and other information published under News. In our image gallery you will find our most recent images and information for media contacts.

Read More

Investors

AroCell AB is located in Uppsala, Sweden. We develop and commercialize tests that can be used in the prognosis, monitoring and follow-up of cancer. The AroCell share is listed on the Swedish Aktietorget.

Read More